Tuesday, November 09, 2021 2:49:37 PM
HoPES Phase II Trial in Sarcoma
In early 2020, the open-label Phase 2 investigator sponsored trial of SM-88 therapy in sarcoma, ….
(1) The first is SM-88 with Methoxsalen*, Phenytoin**, and Sirolimus*** (MPS) as salvage treatment in patients with mixed rare sarcoma.
(2) The other is SM-88 with MPS as maintenance treatment for patients with metastatic Ewing’s sarcoma that had not progressed on prior therapy.[/quote]
The primary objectives are to measure:
………Objective Response Rate (ORR) and
……….Progression Free Survival (PFS).
Secondary objectives include:
……..Duration Of Response (DOR)
……..Overall Survival (OS)
……..Clinical Benefit Rate (CBR) using RECIST (Response Evaluation Criteria In Solid Tumors)[/quote]
Plus incidence of treatment-emergent Adverse Events (AEs).
The Joseph Ahmed Foundation is sponsoring this trial and the trial is being conducted by PI Dr.Chawla at the Sarcoma Oncology Center in Santa Monica, CA.
We anticipate that the trial will complete enrollment by the end of the first half of calendar year 2022.
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM